Eusol Biotech Co (ROCO:6652) Long-Term Capital Lease Obligation : NT$0.00 Mil (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Eusol Biotech Co Long-Term Capital Lease Obligation?

Eusol Biotech Co's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2024 was NT$0.00 Mil.

Eusol Biotech Co's quarterly Long-Term Capital Lease Obligation declined from Dec. 2023 (NT$1.61 Mil) to Jun. 2024 (NT$0.40 Mil) and declined from Jun. 2024 (NT$0.40 Mil) to Dec. 2024 (NT$0.00 Mil).

Eusol Biotech Co's annual Long-Term Capital Lease Obligation declined from Dec. 2022 (NT$3.97 Mil) to Dec. 2023 (NT$1.61 Mil) and declined from Dec. 2023 (NT$1.61 Mil) to Dec. 2024 (NT$0.00 Mil).

Eusol Biotech Co Long-Term Capital Lease Obligation Historical Data

The historical data trend for Eusol Biotech Co's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eusol Biotech Co Long-Term Capital Lease Obligation Chart

Eusol Biotech Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

3.86

0.75

3.97

1.61

Eusol Biotech Co Semi-Annual Data
	Dec15	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial													3.97	2.79	1.61	0.40	-

Eusol Biotech Co (ROCO:6652) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Eusol Biotech Co Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Eusol Biotech Co's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Eusol Biotech Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eusol Biotech Co Ltd (ROCO:6652) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.135, Section 3, Minsheng East Road, 6th Floor, Songshan District, Taipei, TWN, 10546

Website

https://www.eusol.com.tw

Eusol Biotech Co Ltd is a Taiwan based company that invests in developing new drugs to fulfill unmet medical needs. Its pipeline products include ES135, a recombinant human acidic fibroblast growth factor (rhFGF1) with 135 amino acids; and SM-1, a 3-in-1 capsule containing 3 commercial drugs with the sedative effect.

Eusol Biotech Co Headlines

No Headlines